23:01:27 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-28 Ordinarie utdelning CESSA 0.00 DKK
2024-03-27 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-12 Kvartalsrapport 2023-Q1
2023-03-24 Ordinarie utdelning CESSA 0.00 DKK
2023-03-23 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-11-04 Extra Bolagsstämma 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-04-19 Kvartalsrapport 2022-Q1
2022-03-18 Ordinarie utdelning CESSA 0.00 DKK
2022-03-17 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-19 Kvartalsrapport 2021-Q1
2021-03-29 Ordinarie utdelning CESSA 0.00 DKK
2021-03-26 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriBioteknik
Cessatech är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av smärtstillande nässpray som vidare används för behandling av akuta smärttillstånd hos barn. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och relaterade produkter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-03-23 14:00:00

Cessatech A/S, CVR no. 41293055 ("Cessatech" or the "Company") held its Annual General Meeting on Thursday 23 March 2023 at 09:00 (CET) at the Company's address Kanonbådsvej 2, 1437 København K.

The agenda for the general meeting was as follows:

1. ELECTION OF CHAIRMAN OF THE MEETING
1. Mikkel Rostock-Jensen was elected chairman of the meeting. The chairman of the meeting ascertained that none of the shareholders objected to the legality of the annual general meeting and announced that the annual general meeting had been duly convened and was legal and competent in terms of all items on the agenda. The chairman of the general meeting then informed that based on postal votes and proxies duly received prior to the general meeting a solid support of all proposals on the agenda had been secured in advance of the meeting.

2. REPORT ON THE ACTIVITIES OF THE COMPANY IN THE PAST FINANCIAL YEAR
1. The report on the Company's activities in 2022 was noted by the general meeting.

3. PRESENTATION OF THE ANNUAL REPORT WITH AUDITORS' REPORT FOR ADOPTION
1. The general meeting unanimously adopted the audited annual report with auditors' report for 2022

4. RESOLUTION ON COVERING OF LOSSES IN ACCORDANCE WITH THE ADOPTED ANNUAL REPORT
1. The general meeting unanimously resolved that the consolidated loss for the financial year 2022 of tDKK 17,589 is carried forward to the next financial year in accordance with the adopted annual report

5. ELECTION OF MEMBERS TO THE BOARD OF DIRECTORS
1. The general meeting unanimously decided to re-elect Adam Steensberg, Martin Olin, Peter Birk, Charlotte Videbæk, Flemming Steen Jensen and Rachel Curtis Gravesen. For the purpose of these minutes, the chairman noted that the board of directors are subsequently expected to elect Martin Olin as chairman of the board of directors.

6. ELECTION OF AUDITOR
1. The general meeting unanimously re-elected PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, CVR no. 41293055, as the Company's auditor

7. PROPOSALS FROM THE BOARD OF DIRECTORS AND SHAREHOLDERS
1. Prolongation of the authorisation to increase the share capital

The board of directors adopted to prolong the existing authorization of clause 3.2.1 so that it expires on 23 March 2028 and to make an adjustment (for clarification purposes only) to the wording as stated below:

3.2.1. Authorization to cash increase of the share capital: In the period until 23 March 2028, the board of directors is authorized to increase the Company's share capital in one or more issues of new shares at a price equal to market price with-out pre-emption rights for the Company's existing shareholders by up to a nominal amount of DKK 3,667,521.

The chairman of the general meeting announced that all the agenda items had been discussed and announced that the annual general meeting had come to an end.

As chairman of the annual general meeting:

Mikkel Rostock-Jensen